Evidence map›Paper›PMID 38229104›Full record

ArticleBreast cancer research : BCR2024

Evidence of steady-state fibroblast subtypes in the normal human breast as cells-of-origin for perturbed-state fibroblasts in breast cancer.

Mikkel Morsing Bagger, Jonas Sjölund, Jiyoung Kim, Katharina Theresa Kohler, René Villadsen, Abbas Jafari, Moustapha Kassem, Kristian Pietras, Lone Rønnov-Jessen, Ole William Petersen

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. The fibroinflammatory response in cancer.Nature reviews. Cancer · 2025
    Review
  3. Article
  4. CD105Breast cancer research : BCR · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Mikkel Morsing BaggerDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre, Lund University, Lund, Sweden. mikkel.morsing@med.lu.se.ORCID 0000-0001-8322-8796
Jonas SjölundDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre, Lund University, Lund, Sweden.ORCID 0000-0002-6992-3415
Jiyoung KimDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0049-2039
Katharina Theresa KohlerDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-5417-2495
René VilladsenDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-5226-381X
Abbas JafariDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-2443-6231
Moustapha KassemDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-1557-0869
Kristian PietrasDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University Cancer Centre, Lund University, Lund, Sweden.ORCID 0000-0001-6738-4705
Lone Rønnov-JessenSection for Cell Biology and Physiology, Department of Biology, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0002-0472-9320
Ole William PetersenDepartment of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0003-1691-749X
University of Copenhagen · DKLund University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman breast cancer most frequently originates within a well-defined anatomical structure referred to as the terminal duct lobular unit (TDLU). This structure is endowed with its very own lobular fibroblasts representing one out of two steady-state fibroblast subtypes-the other being interlobular fibroblasts. While cancer-associated fibroblasts (CAFs) are increasingly appreciated as covering a spectrum of perturbed states, we lack a coherent understanding of their relationship-if any-with the steady-state fibroblast subtypes. To address this, we here established two autologous CAF lines representing inflammatory CAFs (iCAFs) and myofibroblast CAFs (myCAFs) and compared them with already established interlobular- and lobular fibroblasts with respect to their origin and impact on tumor formation.

methodsPrimary breast tumor-derived CAFs were transduced to express human telomerase reverse transcriptase (hTERT) and sorted into CD105

resultsWe demonstrate that iCAFs have properties in common with interlobular fibroblasts while myCAFs and lobular fibroblasts are related. None of the CAFs qualify as bMSCs as revealed by lack of critical performance in bone formation assays. Functionally, myCAFs and lobular fibroblasts are almost equally tumor promoting as opposed to iCAFs and interlobular fibroblasts. A myCAF gene signature is found to associate with poor breast cancer-specific survival.

conclusionsWe propose that iCAFs and myCAFs originate in interlobular and lobular fibroblasts, respectively, and more importantly, that the tumor-promoting properties of lobular fibroblasts render the TDLU an epicenter for breast cancer evolution.

Indexed as

Breast NeoplasmsCancer-Associated FibroblastsAnimalsBreastFemaleFibroblastsHumansMiceOsteogenesisTumor MicroenvironmentBreast cancerCancer-associated fibroblastCell lineFibroblastiCAFmyCAFTDLU

Identifiers

PMID38229104
PMCPMC10790388
OpenAlexW4390918071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.